Keros Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Keros Therapeutics, Inc. (KROS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-187.35-152.99-104.68-58.74-45.36
Depreciation & Amortization1.230.821.620.380.28
Stock Based Compensation34.8728.7618.6811.724.10
Change in Working Capital-11.44-2.6518.02-16.072.28
Change in Accounts Receivable-2.60-0.1418.00-18.000.00
Change in Accounts Payable-0.251.61-0.411.490.06
Change in Other Working Capital-8.591.55-3.280.452.21
Other Operating Activities1.821.5514.970.521.82
Net Cash from Operating Activities-160.87-124.51-70.06-62.15-36.89
Investing Activities
Capital Expenditures-1.93-2.461.24-1.02-0.29
Net Cash from Investing Activities-1.93-2.46-1.24-1.02-0.29
Financing Activities
Common Stock Issued392.28175.83120.4028.55259.94
Other Financing Activities-0.45-0.09-0.090.00-19.89
Net Cash from Financing Activities391.82178.96120.3128.55296.04
Summary
Net Change in Cash229.0251.9849.01-34.62258.86
Cash at Beginning of Period332.36280.38231.37265.997.14
Cash at End of Period561.38332.36231.37231.377.14
Free Cash Flow-162.80-126.97-71.30-63.17-37.19